Health

Juul ordered to halt sale of electronic cigarette products in U.S.

U.S. federal health officials on Thursday ordered Juul to pull its electronic cigarettes from the market, the latest blow to the embattled company widely blamed for sparking a national surge in teen vaping.

Action part of sweeping effort by U.S. FDA to bring scientific scrutiny to vaping industry

A neon sign in a storefront spells out Juul, the name of an e-cigarette company.
A sign in New York City advertises Juul products in December 2019. U.S. federal health officials on Thursday ordered Juul to pull its electronic cigarettes from the national market. (Stephanie Keith/Getty Images)

U.S. federal health officials on Thursday ordered Juul to pull its electronic cigarettes from the market, the latest blow to the embattled company widely blamed for sparking a national surge in teen vaping.

The action is part of a sweeping effort by the U.S. Food and Drug Administration (FDA) to bring scientific scrutiny to the multibillion-dollar vaping industry after years of regulatory delays.

The FDA said Juul must stop selling its vaping device and its tobacco- and menthol-flavoured cartridges. Those already on the market must be removed. Consumers aren't restricted from having or using Juul's products, the agency said.

To stay on the market, companies must show that their e-cigarettes benefit public health. In practice, that means proving that adult smokers who use the devices are likely to quit or reduce their smoking, while teens are unlikely to get hooked on them.

The FDA noted that some of the biggest sellers like Juul may have played a "disproportionate" role in the rise in teen vaping. The agency said Thursday that Juul's application didn't have enough evidence to show that marketing its products "would be appropriate for the protection of the public health."

Juul said it disagrees with the FDA's findings and will seek to put the ban on hold while the company considers its options, including a possible appeal and talking with regulators.

'Insufficient and conflicting data'

In a statement, the FDA said Juul's application left regulators with significant questions and didn't include enough information to evaluate any potential risks.

The agency said the company's research included "insufficient and conflicting data" about things like potentially harmful chemicals leaching from Juul's cartridges.

"Without the data needed to determine relevant health risks, the FDA is issuing these marketing denial orders." Michele Mital, acting director of the FDA's tobacco centre, said in the statement.

Joe Murillo, Juul's chief regulatory officer, said in the company's statement that Juul submitted enough information and data to address all issues raised by regulators. He noted that the company's application, submitted more than two years ago, included comparisons to combustible cigarettes and other products.

He said it also included information on potential harmful effects of the company's products.

Since last fall, the FDA has given its OK to tobacco-flavoured e-cigarettes from R.J. Reynolds, Logic and other companies.

A woman holds an e-cigarette device and exhales a puff of vapor.
A woman exhales a puff of vapor from a Juul pen in Vancouver, Wash., in April 2019. The U.S. FDA said Thursday that Juul didn't have enough evidence to show that marketing its products 'would be appropriate for the protection of the public health.' (Craig Mitchelldyer/The Associated Press)

But industry players and anti-tobacco advocates have complained that those products account for just a tiny portion of the $6-billion US vaping market in the U.S.

The agency said Thursday that people who use Juul products or smokers who want to move away from cigarettes and cigars could switch to the FDA-authorized e-cigarettes.

Regulators repeatedly delayed making decisions on devices from market leaders, including Juul, which remains the best-selling vaping brand although sales have dipped.

Last year, the agency rejected applications for more than a million other e-cigarettes and related products, mainly due to their potential appeal to underage teens.

Anti-tobacco groups applauded the FDA's move, with the American Lung Association calling it "long overdue and most welcome." The American Vapor Manufacturers Association said it was a "shameful decision."

The rapid rise of vaping

E-cigarettes first appeared in the U.S. more than a decade ago with the promise of providing smokers a less harmful alternative. The devices heat a nicotine solution into a vapour that's inhaled, bypassing many of the toxic chemicals produced by burning tobacco.

But studies have reached conflicting results about whether they truly help smokers quit. And efforts by the FDA to rule on vaping products and their claims were repeatedly slowed by industry lobbying and competing political interests.

The vaping market grew to include hundreds of companies selling an array of devices and nicotine solutions in various flavours and strengths.

The vaping issue took on new urgency in 2018 when Juul's high-nicotine, fruity-flavoured cartridges quickly became a nationwide craze among middle and high school students.

The company faces a slew of federal and state investigations into its early marketing practices, which included distributing free Juul products at concerts and parties hosted by young influencers.

In 2019, the company was pressured into halting all advertising and eliminating its fruit and dessert flavours. The next year, the FDA limited flavours in small vaping devices to just tobacco and menthol. Separately, the U.S. Congress raised the purchase age for all tobacco and vaping products to 21.

But the question of whether e-cigarettes should remain on the market at all remained.

The FDA has been working under a court order to render its decisions; anti-tobacco groups successfully sued the agency to speed up its review.

Kenneth Warner, a tobacco expert at the University of Michigan's school of public health, suspects political pressure from those groups played a role in the FDA's decision.

"I think they would have had a hard time coming to any other conclusion," said Warner, who had not seen Juul's application. He added that he does not take tobacco money.

In response, an FDA spokesman said the company didn't provide enough information for a full risk assessment of its products, and that alone would prevent the agency from finding in favour of Juul.